Sunday, October 26, 2014

Vital Therapies prices follow-on offering


Vital Therapies prices follow-on offering


October 3, 2014 by · Leave a Comment 

Tweet Vital Therapies (NASDAQ:VTL) has priced a follow-on public offering of two million common shares at a price of $17.50 each and granted underwriters a 30-day option to purchase up to an additional 300,000 shares. BofA Merrill Lynch is acting as sole book-running manager for the offering. William Blair is acting as lead manager and Canaccord […]

Continuum of care to drive future NOVADAQ imaging growth

Continuum of care to drive future NOVADAQ imaging growth

September 9, 2014 by · Leave a Comment 

Tweet NOVADAQ Technologies (NASDAQ:NVDQ; TSX:NDQ), pioneers in fluorescence imaging solutions for the operating room, is now focused on manufacturing and directly marketing and selling imaging solutions for use at multiple points throughout the patient care continuum. “Our continuum of care includes diagnostics that can be performed at outpatient clinics and by primary care physicians, where […]

Canaccord upgrades AngioDynamics to buy

Canaccord upgrades AngioDynamics to buy

June 19, 2014 by · Leave a Comment 

Tweet Canaccord Genuity has upgraded AngioDynamics (NASDAQ:ANGO) to “buy” from “hold” and raised its 12-month price target to $20 from $16.25 after the company received FDA approval for the Celerity tip location system. The stock closed at $15.31 on Wednesday. “We believe improving business trends and strong cash generation will drive growth over the next […]

Stifel, Canaccord start TriVascular Technologies at buy

Stifel, Canaccord start TriVascular Technologies at buy

May 12, 2014 by · Leave a Comment 

Tweet Stifel and Canaccord Genuity have launched coverage of TriVascular Technologies (NASDAQ:TRIV) with “buy” ratings and 12-month price targets of $17 and $20, respectively. The stock closed at $12.92 on Friday. “We see TriVascular as a compelling technology and outsized revenue growth story,” writes Stifel analyst Rick Wise. In his report, Canaccord analyst Jason Mills calls […]

Venaxis prices $20-million equity offering

Venaxis prices $20-million equity offering

April 3, 2014 by · Leave a Comment 

Tweet Venaxis (NASDAQ:APPY) has priced a public offering of 8,335,000 common shares at a price of $2.40 each and given underwriters a 30-day option to purchase up to an additional 1,250,250 shares to cover over-allotments, if any. Net proceeds are expected to be approximately $18.4-million. Proceeds will be used for working capital and other general corporate […]

Canaccord cuts Sunshine Heart target to $10

Canaccord cuts Sunshine Heart target to $10

March 11, 2014 by · Leave a Comment 

Tweet Canaccord Genuity has lowered its price target for “buy-rated” Sunshine Heart (NASDAQ:SSH) to $10 from $14.75, reflecting more conservative out-year revenue targets. The stock was quoted at $6.34, down 21%, on Tuesday afternoon. Analyst Jason Mills writes cites a corporate update that “served as a reminder that the company is still in the early […]

Venaxis pivotal APPY1 data due in March

Venaxis pivotal APPY1 data due in March

February 4, 2014 by · Leave a Comment 

Tweet Venaxis (NASDAQ:APPY) expects to report top-line data in March from a pivotal study of its rapid, protein biomarker-based assay for appendicitis, the APPY1 Test and, depending on the results, submit a final data package to the FDA soon after. “We continue to have very positive dialogue with emergency room physicians and administrators at leading hospitals in the […]

Canaccord ups Transition to speculative buy

Canaccord ups Transition to speculative buy

December 10, 2013 by · Leave a Comment 

Tweet Canaccord Genuity has upgraded Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) to “speculative buy” from “hold” and raised its price target to $9.80 from $4.75. The stock closed at $5.86 on the TSX on Monday. “We have taken a closer look at [Transition’s] ELND-005 after attending the Clinical Trials on Alzheimer’s Disease (AD) conference and recently having […]

Canaccord cuts Oncolytics price target

Canaccord cuts Oncolytics price target

November 22, 2013 by · Leave a Comment 

Tweet Canaccord Genuity has lowered its price target for “buy-rated” Oncolytics Biotech (NASDAQ:ONCY; TSX:ONC) to $6.50 from $8 after the company reported top-line head and neck cancer data that raised “more questions than answers.” Analyst Neil Maruoka writes that while the company reported positive median progression free survival for its Reolysin drug candidate, “limited detail, […]

Canaccord ups Novadaq target to $22

Canaccord ups Novadaq target to $22

October 23, 2013 by · Leave a Comment 

Tweet Canaccord Genuity has raised its price target for “buy-rated” Novadaq Technologies (NASDAQ:NVDQ; TSX;NDQ) to $22 from $18 after the company’s third quarter report beat consensus estimates. The stock closed at $16.18 on Tuesday. “We continue to believe that Novadaq possesses one of the most attractive, emerging technologies in med-tech, and possesses the largest, least-penetrated […]

Next Page »

Email Newsletters with Constant Contact
Google+